News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cappella Medical Devices Ltd Announces Excellent Long Term Follow-Up Results for Its Sideguard® Technology at TCT 2012


10/22/2012 9:31:16 AM

GALWAY, Ireland--(BUSINESS WIRE)--Cappella Medical Devices Ltd (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, today announced the multicenter long term follow up results for its innovative SideguardĀ® coronary sidebranch stent . Long term follow up data on the Sideguard stent was obtained from 399 patients from the United Kingdom, Germany, and Italy. The MACE rate was: 3.7% (30 day F/U), 7.1% (6 mo F/U) and 10.2% (1 year F/U) comparing favourably with existing standard practice.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES